Package Leaflet: Information for the Patient
Fesoterodina Edest 4mg prolonged-release tablets EFG
Fesoterodina Edest 8mg prolonged-release tablets EFG
Fesoterodine fumarate
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the Package Leaflet
Fesoterodina Edest contains the active substance fesoterodine fumarate and is a treatment called antimuscarinics, which reduce the activity of the overactive bladder and is used in adults to treat symptoms.
Fesoterodina treats symptoms of an overactive bladder, such as:
Do not take Fesoterodina Edest if:
Warnings and precautions
Consult your doctor or pharmacist before starting to take fesoterodine.
Fesoterodina may not always be suitable for you. Talk to your doctor before taking fesoterodina in any of the following cases:
Cardiac problems: Inform your doctor if you have any of the following conditions:
Children and adolescents
Do not give this medication to children and adolescents under 18 years of age, as it has not been established whether it is effective and safe for them.
Other medications and Fesoterodina Edest
Tell your doctor or pharmacist if you are taking or have recently taken or may need to take other medications. Your doctor will tell you if you can use fesoterodine with other medications.
Please inform your doctor if you are taking medications from the list below.
Taking these medications at the same time as fesoterodine may cause side effects such as dry mouth, constipation, difficulty emptying the bladder, or more severe or frequent drowsiness.
Please indicate to your doctor if you are taking any of the following medications:
Pregnancy and breastfeeding
You should not take fesoterodine if you are pregnant, as the effects of fesoterodine on pregnancy and the newborn are unknown.
It is unknown whether fesoterodine is excreted in breast milk; therefore, do not breastfeed during treatment with fesoterodine.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Driving and using machines
Fesoterodine may cause blurred vision, dizziness, and drowsiness. If you experience any of these effects, do not drive or operate tools or machines.
Fesoterodina Edest contains lactose and soy lecithin
This medication contains lactose. If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
This medication contains soy lecithin. Do not use this medication if you are allergic to peanuts or soy.
Follow your doctor's instructions for taking this medication exactly.
If in doubt, consult your doctor or pharmacist again.
The recommended initial dose of fesoterodine is one 4 mg tablet per day. Depending on how you respond to the medication, your doctor may prescribe a higher dose; one 8 mg tablet per day.
Swallow the tablet whole with a glass of water. Do not chew the tablet. Fesoterodina can be taken with or without food.
To help you remember to take your medication, it may be easier to take it at the same time every day.
If you take more Fesoterodina Edest than you should
If you have taken more tablets than you should or if someone else has taken your tablets by accident, contact your doctor or hospital immediately. Show them the package of tablets.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take Fesoterodina Edest
If you have forgotten to take a tablet, take it as soon as you remember, but do not take more than one tablet in a day. Do not take a double dose to make up for forgotten doses.
If you stop taking Fesoterodina Edest
Do not stop taking fesoterodine without talking to your doctor first, as the symptoms of an overactive bladder may return or worsen when you stop taking fesoterodine.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone will experience them.
Some side effects can be serious
Rarely, severe allergic reactions, including angioedema, may occur. You should stop taking fesoterodine and contact your doctor immediately if you develop swelling in the face, mouth, or throat.
Other side effects
Very common(may affect more than 1 in 10 people):
You may notice dry mouth. This effect is usually mild or moderate. This may increase the risk of tooth decay. Therefore, you should brush your teeth regularly, twice a day, and visit a dentist if in doubt.
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Reporting side effects
If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this package leaflet. You can also report them directly through the Spanish Medication Surveillance System for Human Use: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date shown on the box and blister pack after EXP. The expiration date is the last day of the month indicated.
No special storage conditions are required.
Medications should not be disposed of through wastewater or household waste. Deposit the packaging and any unused medication in the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and any unused medication. This will help protect the environment.
Composition of Fesoterodina Edest
Fesoterodina Edest 4mg prolonged-release tablets EFG:
Each prolonged-release tablet contains 4 mg of fesoterodine fumarate, equivalent to 3.1 mg of fesoterodine.
Fesoterodina Edest 8mg prolonged-release tablets EFG:
Each prolonged-release tablet contains 8 mg of fesoterodine fumarate, equivalent to 6.2 mg of fesoterodine.
Core of the tablet:silicon dioxide, microcrystalline cellulose, hypromellose, lactose, and magnesium stearate.
Coating of the 4 mg tablet:poly(vinyl alcohol), titanium dioxide (E171), talc, soy lecithin, yellow iron oxide (E172), and xanthan gum.
Coating of the 8 mg tablet:poly(vinyl alcohol), titanium dioxide (E171), talc, soy lecithin, carmine indigo (E132), and xanthan gum.
Appearance of the product and package contents
Fesoterodina Edest 4mg prolonged-release tablets EFG:
The 4 mg tablets are yellow, oval-shaped, 13.2 mm long, and 6.65 mm wide, film-coated, and have the letters "FI" engraved on one side and are smooth on the other.
Fesoterodina Edest 8mg prolonged-release tablets EFG:
The 8 mg tablets are blue, oval-shaped, 13.2 mm long, and 6.65 mm wide, film-coated, and have the letters "F II" engraved on one side and are smooth on the other.
Fesoterodina Edest 4 mg and 8 mg are packaged in aluminum-aluminum blisters in a cardboard box containing 28 tablets.
Marketing authorization holder and manufacturer
Marketing authorization holder
Intas Third Party Sales 2005 S.L.
Calle Moll de Barcelona S/N
Edificio World Trade Center
08039 – Barcelona
Spain
Manufacturer
Laboratori Fundació Dau
C/ C, 12-14 Pol. Industrial Zona Franca
08040, Barcelona,
Spain
Date of the last revision of this package leaflet: March 2023
Detailed information about this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es.